Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 2
1981 7
1982 3
1983 6
1984 3
1985 5
1986 8
1987 10
1988 10
1989 11
1990 13
1991 22
1992 21
1993 17
1994 25
1995 32
1996 25
1997 41
1998 49
1999 54
2000 82
2001 97
2002 119
2003 155
2004 209
2005 226
2006 278
2007 354
2008 427
2009 489
2010 526
2011 618
2012 703
2013 798
2014 912
2015 1031
2016 1066
2017 1257
2018 1456
2019 1647
2020 1992
2021 2250
2022 2623
2023 2469
2024 2726
2025 73

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,338 results

Results by year

Filters applied: . Clear all
Page 1
Acupuncture for cancer pain: an evidence-based clinical practice guideline.
Ge L, Wang Q, He Y, Wu D, Zhou Q, Xu N, Yang K, Chen Y, Zhang AL, Hua H, Huang J, Hui KK, Liang F, Wang L, Xu B, Yang Y, Zhang W, Zhao B, Zhu B, Guo X, Xue CC, Zhang H; International Trustworthy traditional Chinese Medicine Recommendations (TCM Recs) Working Group. Ge L, et al. Among authors: zhou q. Chin Med. 2022 Jan 5;17(1):8. doi: 10.1186/s13020-021-00558-4. Chin Med. 2022. PMID: 34983587 Free PMC article. Review.
Palladium(II)-Initiated Catellani-Type Reactions.
Cheng HG, Chen S, Chen R, Zhou Q. Cheng HG, et al. Among authors: zhou q. Angew Chem Int Ed Engl. 2019 Apr 23;58(18):5832-5844. doi: 10.1002/anie.201813491. Epub 2019 Feb 20. Angew Chem Int Ed Engl. 2019. PMID: 30589184 Review.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
22,338 results
You have reached the last available page of results. Please see the User Guide for more information.